Seattle Genetics, Inc. – Lymphoma, T-Cell, Cutaneous

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The purpose of this study is to provide the option of brentuximab vedotin treatment to
eligible patients in studies SGN35-005 and C25001

Rare Disease:
Cutaneous T-cell lymphoma